Experience with Cryopreserved Cadaveric Femoral Vein Allografts Used for Hemodialysis Access

Madden, Robert L.; Lipkowitz, George S.; Browne, Barry J.; Kurbanov, Alexander

doi:10.1007/s10016-004-0055-0

Cited by 54 publications

(52 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, others have reported allogenic DSs show low immunogenicity in vivo (19), and more resistance to infection than PTFE graft when used as hemodialysis access (20). Furthermore, we immobilized heparin to the DSs using EDC and NHS as cross-link agents.…”

Section: Vascular Tissue Engineering From Decellularized Scaffold 235mentioning

confidence: 92%

Development and Validation of Small‐diameter Vascular Tissue From a Decellularized Scaffold Coated With Heparin and Vascular Endothelial Growth Factor

et al. 2009

View full text Add to dashboard Cite

To overcome shortcomings of current small-diameter vascular prostheses, we developed a novel allogenic vascular graft from a decellularized scaffold modified through heparin immobilization and vascular endothelial growth factor (VEGF) coating. The VEGF coating and release profiles were assayed by enzyme-linked immunosorbent assay, the biological activity of modified surface was validated by human umbilical vein endothelial cells seeding and proliferation for 10 days in vitro. In vivo, we implanted either a modified or a nonmodified scaffold as bilateral carotid allogenic graft in canines (n = 15). The morphological examination of decellularized scaffolds showed complete removal of cellular components while the extracellular matrix structure remained intact. After modification, the scaffolds possessed local sustained release of VEGF up to 20 days, on which the cells cultured showed significantly higher proliferation rate throughout the time after incubation compared with the cells cultured on nonmodified scaffolds (P < 0.0001). After 6 months of implantation, the luminal surfaces of modified scaffolds exhibited complete endothelium regeneration, however, only a few disorderly cells and thrombosis overlay the luminal surfaces of nonmodified scaffolds. Specifically, the modified scaffolds exhibited significantly smaller hyperplastic neointima area compared with the nonmodified, not only at midportion (0.56 +/- 0.07 vs. 2.04 +/- 0.12 mm(2), P < 0.0001), but also at anastomotic sites (1.76 +/- 0.12 vs. 3.67 +/- 0.20 mm(2), P < 0.0001). Moreover, modified scaffolds had a significantly higher patency rate than the nonmodified after 6 months of implantation (14/15 vs. 7/15, P = 0.005). Overall, this modified decellularized scaffold provides a promising direction for fabrication of small-diameter vascular grafts.

show abstract

Section: Vascular Tissue Engineering From Decellularized Scaffold 235mentioning

confidence: 92%

Development and Validation of Small‐diameter Vascular Tissue From a Decellularized Scaffold Coated With Heparin and Vascular Endothelial Growth Factor

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The clinical signs of allograft rejection did not occur 93 . The potential of cryopreserved vein grafts were also evaluated in 2004 and 2005 by Madden et al 94,95 . In their first work they compared the outcomes of ePTFE grafts and cryopreserved veins in infectionfree field.…”

Section: Graft Infection Therapymentioning

confidence: 99%

INFECTIOUS COMPLICATIONS OF ARTERIOVENOUS ePTFE GRAFTS FOR HEMODIALYSIS

Bachleda¹,

Utíkal²,

Kalinová³

et al. 2010

BIOMED PAP

View full text Add to dashboard Cite

“…14,15 Historically, concerns regarding the use of cadaveric vein for dialysis access included a reported increased tendency for pseudoaneurysm formation and subsequent rupture risk as well as a possible propensity for steal syndrome secondary to the cadaveric veins larger diameter. 4 In this current series, we found our pseudoaneurysm rate to be 4.8% referenced in our results by rate of rupture (Table III). In reviewing the literature, reported rates for pseudoaneurysm formation for PTFE range from 2% to 10%.…”

Section: Access Abandonmentmentioning

confidence: 46%

An Outcomes Comparison of Native Arteriovenous Fistulae, Polytetrafluorethylene Grafts, and Cryopreserved Vein Allografts

Jadlowiec

Lavallee

Mannion

et al. 2015

Annals of Vascular Surgery

View full text Add to dashboard Cite

Experience with Cryopreserved Cadaveric Femoral Vein Allografts Used for Hemodialysis Access

Cited by 54 publications

References 11 publications

Development and Validation of Small‐diameter Vascular Tissue From a Decellularized Scaffold Coated With Heparin and Vascular Endothelial Growth Factor

Development and Validation of Small‐diameter Vascular Tissue From a Decellularized Scaffold Coated With Heparin and Vascular Endothelial Growth Factor

INFECTIOUS COMPLICATIONS OF ARTERIOVENOUS ePTFE GRAFTS FOR HEMODIALYSIS

An Outcomes Comparison of Native Arteriovenous Fistulae, Polytetrafluorethylene Grafts, and Cryopreserved Vein Allografts

Contact Info

Product

Resources

About